Markets

Biotech ETF (CNCR) Hits New 52-Week High

For investors seeking momentum, Loncar Cancer Immunotherapy ETF CNCR is probably on radar now. The fund just hit a 52-week high and is up nearly 37.4% from its 52-week low price of $21.09/share.

But are more gains in store for this ETF? Let's take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:

CNCR in Focus

This fund provides exposure to companies that develop therapies to treat cancer by harnessing the body's own immune system. Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care. CNCR charges 79 bps in fees per year from its investors (see: all the Healthcare ETFs here ).

Why the Move?

The biotech segment of the broad equity market has been an area to watch lately, given encouraging industry fundamentals including mergers and acquisitions, earnings growth, promising drug launches, faster drug approvals, cost-cutting efforts, an aging population and Trump's tax reform. In particular, the new tax legislation enticed companies to bring offshore cash back home, leading to a wave of mergers and acquisitions.

More Gains Ahead?

CNCR has a Zacks ETF Rank #2 (Buy) with a High risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank, so there is definitely still some promise for those who want to ride on this surging ETF a little longer.

Want key ETF info delivered straight to your inbox?

Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LONCAR CANCER (CNCR): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CNCR

Other Topics

ETFs

Latest Markets Videos